<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03127449</url>
  </required_header>
  <id_info>
    <org_study_id>20170405</org_study_id>
    <nct_id>NCT03127449</nct_id>
  </id_info>
  <brief_title>AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations</brief_title>
  <official_title>Multiple-Centered Study of AST2818 in Patients With Advanced Non-small Cell Lung Cancer With EGFR Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allist Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allist Pharmaceuticals, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to assess the safety, tolerability and preliminary efficacy of&#xD;
      AST2818 in patients with advanced Non Small Cell Lung Cancer (NSCLC).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Evaluation of objective response rate assessed by RECIST 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Duration of response assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate progression free survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Clinical benefit rate was calculated by adding up complete remission, partial remission and stabilization of disease assessed by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate of Alflutinib</measure>
    <time_frame>CT or MRI at screening and every 2 Cycles (from first dose of multiple dosing) until disease progression or withdrawal from study, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Progression of tumor was assessed by RECIST 1.1 thereby to evaluate disease control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence and Severity of Treatment-Emergent Adverse Events</measure>
    <time_frame>Adverse events will be collected from baseline until 28 days after the last dose</time_frame>
    <description>Assessed by number and severity of adverse events as recorded on the case report form, vital signs, laboratory variables, physical examination, electrocardiogram, ophthalmic examinations, RECIST1.1, and NCI CTCAE v4.03</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state Maximum Plasma Concentration [Cmax] of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>Cmax of Alflutinib and 2 metabolites at steady state following multiple doses</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state peak plasma time [tmax] of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>tmax of Alflutinib and 2 metabolites at steady state following multiple doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state Cmin (Minimum Plasma Concentration) of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>Cmin of Alflutinib and 2 metabolites at steady state following multiple doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state area under the plasma concentration versus time curve [AUC] of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>AUC of Alflutinib and 2 metabolites at steady state following multiple doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady state clearance of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>Clearance of Alflutinib and 2 metabolites at steady state following multiple doses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio of multiple doses Alflutinib and 2 metabolites</measure>
    <time_frame>Blood samples will be collected from each subject at pre-specified times during the multiple dosing cycles (Cycle 1-pre-dose Day 1, 8, 15. Cycle 2 D1- pre-dose, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72 hours post dose)</time_frame>
    <description>Accumulation ratio of Alflutinib and 2 metabolites following multiple doses.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">116</enrollment>
  <condition>Advanced NSCLC</condition>
  <arm_group>
    <arm_group_label>Alflutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients take Alflutinib orally once per day at different dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alflutinib</intervention_name>
    <description>patients take Alflutinib orally once per day at different dose</description>
    <arm_group_label>Alflutinib</arm_group_label>
    <other_name>AST2818</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients of either gender, aged older than 18 years.&#xD;
&#xD;
          -  Histologically or cytologically confirmed metastatic, or unresectable locally&#xD;
             advanced, recurrent NSCLC.&#xD;
&#xD;
          -  Radiological documentation of disease progression while on a previous continuous&#xD;
             treatment with an EGFR TKI e.g. gefitinib or erlotinib or Afatinib, or Icotinib (Third&#xD;
             EGFR TKI are not included). In addition other lines of therapy may have been given.&#xD;
&#xD;
          -  Confirmation that the tumour harbours an EGFR mutation known to be associated with&#xD;
             EGFR TKI sensitivity (including at least one of G719X, exon 19 deletion, L858R, L861Q&#xD;
             mutation)&#xD;
&#xD;
          -  Documented evidence of definitely EGFR T790M+ state in the tumor tissue after disease&#xD;
             progression on the most recent treatment regimen (irrespective of whether this is EGFR&#xD;
             TKI or chemotherapy).&#xD;
&#xD;
          -  ECOG performance status of 0 to 2. Life expectancy of at least 12 weeks.&#xD;
&#xD;
          -  At least one measurable disease by CT or PET-CT or MRI, according to RECIST Version&#xD;
             1.1.&#xD;
&#xD;
          -  Organ function must meet the following requirementsï¼šAbsolute neutrophil count &gt;= 1.5 x&#xD;
             109/L, Platelet count &gt;= 75 x 109/L, Haemoglobin &gt;= 90 g/Lï¼›Alanine&#xD;
             aminotransferase/Aspartate aminotransferase &lt;= 2.5 times the upper limit of normal if&#xD;
             no demonstrable liver metastases or &lt;= 5 times in the presence of liver&#xD;
             metastasesï¼›Total bilirubin &lt;= 1.5 times ULN if no liver metastases or &lt;= 3 times ULN&#xD;
             in the presence of liver metastases or liver metastasesï¼›Creatinine &lt;=1.5 times ULN&#xD;
             concurrent with creatinine clearance &gt;= 50 ml/min (measured or calculated by Cockcroft&#xD;
             and Gault equation); Females should not be in lactation period and must have a&#xD;
             negative pregnancy test prior to start of dosing; During the whole treatment,all&#xD;
             patients should be in the entire 3 months during and after the treatment, repeated&#xD;
             barrier precautions&#xD;
&#xD;
          -  Signed consent on an Independent Ethics Committee-approved Informed Consent Form prior&#xD;
             to any study-specific evaluation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any cytotoxic chemotherapy from a previous treatment regimen or clinical study within&#xD;
             21 daysï¼ŒAny Target cancer drug from a previous treatment regimen or clinical study&#xD;
             within 14 days, or less than approximately 5x half-life of the first dose of study&#xD;
             treatmentï¼›The third EGFR-TKI from a previous treatment regimen or clinical study (ie,&#xD;
             AZD9291, CO-1686, HM61713, ASP8273, EGF816, avitinib,&#xD;
&#xD;
          -  Taking (or cannot stop taking 1 week before the first dose receiving) strong inhibitor&#xD;
             of CYP3A4 or antitumor herb.&#xD;
&#xD;
          -  Unrecovered toxic reaction due to former therapy existed, with over 1 grade of CTCAE&#xD;
             (except alopecia) or 2 grade if ever applied DDP curing related neuropathy.&#xD;
&#xD;
          -  Spinal compression, or brain metastasis exhibiting symptoms but untreated (except&#xD;
             those exhibit no symptom with stable condition and do not apply corticosteroids for 4&#xD;
             weeks before the trail initiating)&#xD;
&#xD;
          -  Any evidence showing severe or inadequate controlled systemic disease. For example&#xD;
             patients with inadequate controlled hypertension considered not suitable for the trail&#xD;
             or would affect the compliance towards the protocol, with active hemorrhagic tendency,&#xD;
             with active infection such as HBV (HBV-DNAâ‰¥1000cps/ml), with HCV, with HIV et al&#xD;
             (except for HBV carrier those the researcher considered meet the criterion).&#xD;
&#xD;
          -  Any condition affecting the drug taking, or significantly affecting the absorption or&#xD;
             the pharmacokinetic parameters, include any kind of uncontrollable nausea or vomit,&#xD;
             chronic gastroenteropathy, disability in swallowing, and history of gastrointestinal&#xD;
             resection or surgery.&#xD;
&#xD;
          -  Any condition meet the following cardiac standard: ECG show a QTc&gt;470 msec under&#xD;
             resting state (Repeat in 48 hours when a first abnormal discovered, take mean of the&#xD;
             two measurements). All kinds of abnormal in cardiac rhythm, conduction and resting ECG&#xD;
             profile with clinical significance, for example complete left bundle branch block, 2&#xD;
             or 3 grade of conduction block and a PR interval&gt;250 msec. Any possible factors&#xD;
             increasing the risk of QTc extending or leading to arrhythmia, such as heart failure,&#xD;
             hypokalemia, congenital long QT syndrome, any first degree relative suffered from long&#xD;
             QT syndrome or undertook unexplained sudden death before 40 years old, or taking any&#xD;
             drug leading to a longer QTc.&#xD;
&#xD;
          -  Any history of interstitial lung disease, drug induced interstitial lung disease,&#xD;
             radiation pneumonia require steroid therapy or active interstitial lung disease with&#xD;
             clinical evidence during recruiting.&#xD;
&#xD;
          -  Patients with other factors the researchers considered not suitable for the trail (for&#xD;
             example, patients those who not willing to follow the procedure, limitation or&#xD;
             requirements, who once experienced bone marrow allotransplantation, who have other&#xD;
             kinds of malignant tumor coexisted or who showed allergic to the active ingredients or&#xD;
             inactive adjuvant of the investigational drug, as well as drugs with similar chemical&#xD;
             structure or in the same class).&#xD;
&#xD;
          -  Confirmed mutation of EGFR 20 exon insertion at anytime after the first diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>cancer hospital Chinese academy of medical sciences</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>April 18, 2017</study_first_submitted>
  <study_first_submitted_qc>April 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 25, 2017</study_first_posted>
  <last_update_submitted>January 2, 2020</last_update_submitted>
  <last_update_submitted_qc>January 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflutinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

